Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note released on Friday. The firm issued a sell rating on the stock.

Separately, Dawson James initiated coverage on Tonix Pharmaceuticals in a research report on Wednesday, February 28th. They set a buy rating and a $96.00 price target on the stock.

Tonix Pharmaceuticals Price Performance

Shares of Tonix Pharmaceuticals stock opened at $1.15 on Friday. The company has a current ratio of 1.47, a quick ratio of 0.87 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $4.97 and a 200-day simple moving average of $9.13. The stock has a market capitalization of $3.44 million, a price-to-earnings ratio of -0.01 and a beta of 2.16. Tonix Pharmaceuticals has a 1-year low of $1.08 and a 1-year high of $63.68.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Monday, May 13th. The company reported ($5.76) EPS for the quarter, beating the consensus estimate of ($16.64) by $10.88. The firm had revenue of $2.48 million during the quarter, compared to analyst estimates of $4.00 million. On average, sell-side analysts expect that Tonix Pharmaceuticals will post -82.43 earnings per share for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC raised its holdings in Tonix Pharmaceuticals by 260.6% in the first quarter. Acadian Asset Management LLC now owns 335,373 shares of the company’s stock worth $61,000 after purchasing an additional 242,358 shares during the period. Armistice Capital LLC grew its position in shares of Tonix Pharmaceuticals by 160.0% in the 4th quarter. Armistice Capital LLC now owns 3,770,000 shares of the company’s stock valued at $1,519,000 after acquiring an additional 2,320,000 shares during the period. Finally, Sabby Management LLC bought a new position in Tonix Pharmaceuticals during the third quarter worth about $680,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.